Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, plcKNSA · Entity 1954 | CHIEF OPERATING OFFICER | September 01, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kiniksa Pharmaceuticals International, plc
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary ShareSEC Table I · non-derivative | Direct | 16,307 |
Ending reported balance
After 2026-09-01 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-09-01 · Exercise / conversion · Acquired 2,477 · Balance 14,506 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 2 · 2026-09-01 · Exercise / conversion · Acquired 1,611 · Balance 16,117 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 3 · 2026-09-01 · Exercise / conversion · Acquired 1,740 · Balance 17,857 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 4 · 2026-09-01 · Exercise / conversion · Acquired 2,457 · Balance 20,314 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 5 · 2026-09-01 · Tax withholding · Disposed 4,007 · Balance 16,307 |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 9,250 |
Reported balance
After 2026-09-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-01 · Grant · Acquired 9,250 · Balance 9,250 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 7,371 |
Reported balance
After 2026-09-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-01 · Exercise / conversion · Disposed 2,457 · Balance 7,371 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the vesting commencement date September 1, 2025. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 3,481 |
Reported balance
After 2026-09-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-01 · Exercise / conversion · Disposed 1,740 · Balance 3,481 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F5: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2024. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 1,611 |
Reported balance
After 2026-09-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-09-01 · Exercise / conversion · Disposed 1,611 · Balance 1,611 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F6: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-09-01 · Exercise / conversion · Disposed 2,477 · Balance 0 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F7: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. |
| Share OptionSEC Table II · derivative / convertible security · Conversion / exercise price $79.28 · Expires 2036-08-31 | Direct | 36,950 |
Reported balance
After 2026-09-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-01 · Grant · Acquired 36,950 · Balance 36,950 F3: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026.
F3: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026.
F4: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the vesting commencement date September 1, 2025.
F5: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2024.
F6: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023.
F7: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2024 Filed Sep 5, 2024 00:42 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 6,962 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-022854 · form4-09052024_120928.xml · derivative · entry 11 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,962 Underlying: Class A Ordinary Share · 6,962 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F6 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2024. F6 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2024. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:42 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 1,393 | $26.74 | $37,248.82 |
DisclosureSEC source: 0001415889-24-022854 · form4-09052024_120928.xml · nonDerivative · entry 3 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,087 Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:42 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 4,089 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-022854 · form4-09052024_120928.xml · nonDerivative · entry 2 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,480 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| July 15, 2024 Filed Sep 5, 2024 00:42 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantClass A Ordinary Share | 211 | $15.65 | $3,302.15 |
DisclosureSEC source: 0001415889-24-022854 · form4-09052024_120928.xml · nonDerivative · entry 1 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,391 F1 · kind: The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of January 16, 2024 to July 15, 2024. The acquisition of such shares was exempt pursuant to Rule 16b-3(c). Read SEC document |
| April 08, 2024 Filed Apr 8, 2024 21:19 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,477 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-010507 · form4-04082024_090417.xml · derivative · entry 6 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,318 Underlying: Class A Common Share · 2,477 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F6 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. F6 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. Read SEC document |
| April 08, 2024 Filed Apr 8, 2024 21:19 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 1,353 | $17.90 | $24,218.70 |
DisclosureSEC source: 0001415889-24-010507 · form4-04082024_090417.xml · nonDerivative · entry 2 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,276 Read SEC document |
| April 08, 2024 Filed Apr 8, 2024 21:19 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 2,477 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-010507 · form4-04082024_090417.xml · nonDerivative · entry 1 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,629 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| April 04, 2024 Filed Apr 8, 2024 21:19 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 6,962 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-010507 · form4-04082024_090417.xml · derivative · entry 5 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,795 Underlying: Class A Common Share · 6,962 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F5 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2024, and each yearly anniversary thereafter. F5 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2024, and each yearly anniversary thereafter. Read SEC document |
| April 04, 2024 Filed Apr 8, 2024 21:19 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantPerformance Share Unit · Derivative | 5,569 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-010507 · form4-04082024_090417.xml · derivative · entry 4 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,569 Underlying: Class A Common Share · 5,569 shares Expires 2034-03-31 F3 · derivative.exercise_price: Each Performance Share Unit (PSU) represents a contingent right to receive a number of Class A Common Shares of the Issuer based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee. F4 · derivative.exercise_date: Unless earlier forfeited, each PSU vests and converts into not more than 200% of one Class A Common Share of the Issuer no later than January 30, 2027, unless such date falls on a non-business date, in which case the next business date shall apply. Read SEC document |
| April 04, 2024 Filed Apr 8, 2024 21:19 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 36,100 | $0.00 Strike: $18.06 | $0.00 |
DisclosureSEC source: 0001415889-24-010507 · form4-04082024_090417.xml · derivative · entry 3 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,100 Underlying: Class A Common Share · 36,100 shares Expires 2034-03-31 F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal month installments thereafter. The vesting commencement date is April 1, 2024. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 21:20 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,612 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-010079 · form4-04032024_090405.xml · derivative · entry 3 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,833 Underlying: Class A Common Share · 1,612 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date, April 1, 2023. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date, April 1, 2023. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 21:20 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 880 | $19.70 | $17,336.00 |
DisclosureSEC source: 0001415889-24-010079 · form4-04032024_090405.xml · nonDerivative · entry 2 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,152 Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 21:20 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 1,612 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-010079 · form4-04032024_090405.xml · nonDerivative · entry 1 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,032 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| September 02, 2023 Filed Sep 6, 2023 23:07 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 994 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-013046 · form4-09062023_110933.xml · derivative · entry 9 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,988 Underlying: Class A Common Share · 994 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F6 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 2, 2021. F6 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 2, 2021. Read SEC document |
| September 02, 2023 Filed Sep 6, 2023 23:07 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 543 | $17.76 | $9,643.68 |
DisclosureSEC source: 0001415889-23-013046 · form4-09062023_110933.xml · nonDerivative · entry 5 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,420 Read SEC document |
| September 02, 2023 Filed Sep 6, 2023 23:07 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 994 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-013046 · form4-09062023_110933.xml · nonDerivative · entry 4 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,963 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 23:07 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 38,668 | $0.00 Strike: $17.76 | $0.00 |
DisclosureSEC source: 0001415889-23-013046 · form4-09062023_110933.xml · derivative · entry 8 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,668 Underlying: Class A Common Share · 38,668 shares Expires 2033-08-31 F5 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2023. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 23:07 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 6,445 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-013046 · form4-09062023_110933.xml · derivative · entry 7 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,445 Underlying: Class A Common Share · 6,445 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F4 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 1, 2023. F4 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 1, 2023. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 23:07 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,477 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-013046 · form4-09062023_110933.xml · derivative · entry 6 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,431 Underlying: Class A Common Share · 2,477 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 1, 2022. F3 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 1, 2022. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 23:07 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 1,353 | $17.76 | $24,029.28 |
DisclosureSEC source: 0001415889-23-013046 · form4-09062023_110933.xml · nonDerivative · entry 3 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,969 Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 23:07 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 2,477 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-013046 · form4-09062023_110933.xml · nonDerivative · entry 2 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,322 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| July 15, 2023 Filed Sep 6, 2023 23:07 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantClass A Common Share | 292 | $12.35 | $3,606.20 |
DisclosureSEC source: 0001415889-23-013046 · form4-09062023_110933.xml · nonDerivative · entry 1 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,845 F1 · kind: The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of January 16, 2023 to July 15, 2023. The acquisition of such shares was exempt pursuant to Rule 16b-3(c). Read SEC document |
| April 10, 2023 Filed Apr 11, 2023 21:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,477 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-006444 · form4-04112023_090434.xml · derivative · entry 3 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,431 Underlying: Class A Common Share · 2,477 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. Read SEC document |
| April 10, 2023 Filed Apr 11, 2023 21:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 1,353 | $10.71 | $14,490.63 |
DisclosureSEC source: 0001415889-23-006444 · form4-04112023_090434.xml · nonDerivative · entry 2 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,553 Read SEC document |
| April 10, 2023 Filed Apr 11, 2023 21:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 2,477 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-006444 · form4-04112023_090434.xml · nonDerivative · entry 1 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,906 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| April 01, 2023 Filed Apr 3, 2023 20:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 6,445 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-005792 · form4-04032023_040423.xml · derivative · entry 2 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,445 Underlying: Class A Common Share · 6,445 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2023. F3 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2023. Read SEC document |
| April 01, 2023 Filed Apr 3, 2023 20:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 38,668 | $0.00 Strike: $10.76 | $0.00 |
DisclosureSEC source: 0001415889-23-005792 · form4-04032023_040423.xml · derivative · entry 1 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,668 Underlying: Class A Common Share · 38,668 shares Expires 2033-03-31 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2023. Read SEC document |
| March 20, 2023 Filed Mar 20, 2023 21:19 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,137 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-005235 · form4-03202023_090303.xml · derivative · entry 7 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Share · 2,137 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F4 · derivative.exercise_date: The performance criteria for these RSUs were met. The RSUs vested in a single installment on March 20, 2023; there was no expiration date for the RSUs. F4 · derivative.expiration_date: The performance criteria for these RSUs were met. The RSUs vested in a single installment on March 20, 2023; there was no expiration date for the RSUs. Read SEC document |
| March 20, 2023 Filed Mar 20, 2023 21:19 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 1,167 | $11.12 | $12,977.04 |
DisclosureSEC source: 0001415889-23-005235 · form4-03202023_090303.xml · nonDerivative · entry 5 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,429 Read SEC document |
| March 20, 2023 Filed Mar 20, 2023 21:19 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 2,137 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-005235 · form4-03202023_090303.xml · nonDerivative · entry 4 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,596 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| March 16, 2023 Filed Mar 20, 2023 21:19 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 994 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-005235 · form4-03202023_090303.xml · derivative · entry 6 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,988 Underlying: Class A Common Share · 994 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each anniversary of the date of grant, March 16, 2021. F3 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each anniversary of the date of grant, March 16, 2021. Read SEC document |
| March 16, 2023 Filed Mar 20, 2023 21:19 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 543 | $11.46 | $6,222.78 |
DisclosureSEC source: 0001415889-23-005235 · form4-03202023_090303.xml · nonDerivative · entry 3 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,459 Read SEC document |
| March 16, 2023 Filed Mar 20, 2023 21:19 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 994 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-005235 · form4-03202023_090303.xml · nonDerivative · entry 2 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,002 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| January 15, 2023 Filed Mar 20, 2023 21:19 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantClass A Common Share | 1,844 | $9.56 | $17,628.64 |
DisclosureSEC source: 0001415889-23-005235 · form4-03202023_090303.xml · nonDerivative · entry 1 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,008 F1 · kind: The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of July 16, 2022 to January 15, 2023. The acquisition of such shares was exempt pursuant to Rule 16b-3(c). Read SEC document |
| September 02, 2022 Filed Sep 6, 2022 20:12 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 995 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-009353 · form4-09062022_010900.xml · derivative · entry 6 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,982 Underlying: Class A Common Share · 995 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F5 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021. F5 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021. Read SEC document |
| September 02, 2022 Filed Sep 6, 2022 20:12 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 563 | $11.44 | $6,440.72 |
DisclosureSEC source: 0001415889-22-009353 · form4-09062022_010900.xml · nonDerivative · entry 3 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,164 Read SEC document |
| September 02, 2022 Filed Sep 6, 2022 20:12 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 995 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-22-009353 · form4-09062022_010900.xml · nonDerivative · entry 2 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,727 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:12 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 9,908 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-009353 · form4-09062022_010900.xml · derivative · entry 5 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,908 Underlying: Class A Common Share · 9,908 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F4 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. F4 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:12 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 59,460 | $0.00 Strike: $11.97 | $0.00 |
DisclosureSEC source: 0001415889-22-009353 · form4-09062022_010900.xml · derivative · entry 4 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,460 Underlying: Class A Common Share · 59,460 shares Expires 2032-08-31 F3 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2022. Read SEC document |
| July 15, 2022 Filed Sep 6, 2022 20:12 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantClass A Common Share | 360 | $9.56 | $3,441.60 |
DisclosureSEC source: 0001415889-22-009353 · form4-09062022_010900.xml · nonDerivative · entry 1 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,732 F1 · kind: The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of January 16, 2022 to July 15, 2022. The acquisition of such shares was exempt pursuant to Rule 16b-3(c). Read SEC document |
| April 07, 2022 Filed Apr 11, 2022 20:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 9,908 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-003993 · form4-04112022_040417.xml · derivative · entry 2 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,908 Underlying: Class A Common Share · 9,908 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. F3 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. Read SEC document |
| April 07, 2022 Filed Apr 11, 2022 20:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 59,460 | $0.00 Strike: $11.10 | $0.00 |
DisclosureSEC source: 0001415889-22-003993 · form4-04112022_040417.xml · derivative · entry 1 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,460 Underlying: Class A Common Share · 59,460 shares Expires 2032-04-06 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 7, 2022. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 20:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,270 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-003286 · form4-03232022_040326.xml · derivative · entry 3 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Share · 2,270 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F2 · derivative.exercise_date: The performance criteria for these RSUs were met. The RSUs vested in a single installment on March 20, 2022; there was no expiration date for the RSUs. F2 · derivative.expiration_date: The performance criteria for these RSUs were met. The RSUs vested in a single installment on March 20, 2022; there was no expiration date for the RSUs. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 20:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 1,240 | $10.98 | $13,615.20 |
DisclosureSEC source: 0001415889-22-003286 · form4-03232022_040326.xml · nonDerivative · entry 2 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,372 Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 20:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 2,270 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-22-003286 · form4-03232022_040326.xml · nonDerivative · entry 1 Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,612 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:39 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 995 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-002328 · edgar.xml · derivative · entry 5 Moat Ross · CIK 0001857177 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,982 Underlying: Class A Common Share · 995 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F4 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021. F4 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:39 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 544 | $10.13 | $5,510.72 |
DisclosureSEC source: 0001179110-22-002328 · edgar.xml · nonDerivative · entry 4 Moat Ross · CIK 0001857177 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,342 Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:39 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 995 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-22-002328 · edgar.xml · nonDerivative · entry 3 Moat Ross · CIK 0001857177 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,886 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| January 15, 2022 Filed Mar 18, 2022 20:39 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantClass A Common Share | 1,546 | $9.63 | $14,887.98 |
DisclosureSEC source: 0001179110-22-002328 · edgar.xml · nonDerivative · entry 2 Moat Ross · CIK 0001857177 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,891 F2 · kind: The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of July 16, 2021 to January 15, 2022. The acquisition of such shares was exempt pursuant to Rule 16b-3(c). Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 21:16 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Units · Derivative | 3,977 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-008649 · edgar.xml · derivative · entry 2 Moat Ross · CIK 0001857177 · ARCALYST General Manager 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,977 Underlying: Class A Common Shares · 3,977 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Share Unit represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The Restricted Share Units (RSUs) vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021. F3 · derivative.expiration_date: The Restricted Share Units (RSUs) vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.